Mark Capone

Mr Capone is an accomplished life sciences executive with more than 35 years’ experience, most recently serving as President and CEO of Myriad Genetics. While at Myriad, he transformed a pioneering start-up into one of the largest precision medicine companies in the world, bringing both business acumen and technical knowledge to the Microba Life Sciences Board. During his 17-year tenure, the company developed and launched more than a dozen reimbursed molecular diagnostics and achieved total annual revenues of more than $800 million. Prior to Myriad, Mr Capone spent 17 years at Eli Lilly and Company in various positions across the entire value chain. He received his Bachelor of Science in chemical engineering from Penn State University (high distinction) and two Master’s of Science in (bio)chemical engineering and management from Massachusetts Institute of Technology. He currently serves as President and CEO of Precision Medicine Advisors, LLC, is a non-executive board member of Abcam plc, and a non-executive director and executive advisor for NephroSant.